Vectra polaris automated quantitative pathology imaging system
Start date
05 August 2019End date
04 August 2024Project website
ViewPrecision Molecular Pathology Research Services
Our state-of-the-art facility can perform high through put, rapid immunohistochemical techniques for research specimens.
We offer a full workflow for digital pathology from sectioning, staining, slide scanning to image analysis, using our developed 9 plex antibody panels in human tissue. We have experience of working in tonsil, oesophageal, pancreas, bladder, prostate, placenta, ovarian, and endometrial tissue.
Our experienced cooperative team can work with researchers to develop multiplex panels up to 8 markers using the Lecia Bond Rx and Akoya Bioscineces PhenoImager HT. The lab is HTA compliant, using Elab for sample tracking, and carrying work out to good lab practice standards.
Services we offer
- Sectioning FFPF tissue blocks
- Staining Chromogenic and IF: Our lab is equipped with the Lecia Bond RX and can carry out
- Scanning Brightfield and Fluorescence Images: using the PhenoImager HT
- AI mediated analysis using Inform and Qupath
Funders
Team
Principal investigator
Professor Hardev Pandha
Honorary Professor of Urological Oncology
Biography
Hardev Pandha is a clinician scientist and medical oncologist who graduated in medicine at the University of Birmingham. He trained in internal medicine and subsequently in medical oncology at the Royal Postgraduate Medical School at Hammersmith Hospital, London. He completed his PhD (Imperial College) in the Imperial Cancer Research Fund labs at the Hammersmith. He was a visiting fellow at Stanford University prior to completing his medical oncology training at the Royal Marsden Hospital, London. He was a senior lecturer in tumour immunology and medical oncology at St Georges, University of London in 2000 before being appointed Prof of Urological Oncology at the University of Surrey in 2006.
His areas of expertise include the management of patients with Urological cancers and malignant melanoma. He has a key interest in early phase clinical trials involving targeted agents and the translational aspects of novel therapies. His portfolio includes gene and viral therapy as well as immunotherapy and small molecule inhibitors. His laboratory interests reflect this and in particular a combination of novel and biological therapies with more conventional treatments. His lab team have evolved a robust infrastructure of patient sample procurement and biobanking for translational research.
Research themes
Find out more about our research at Surrey: